|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.92 - 3.19|
|52 Week Range||0.92 - 3.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.90|
Stock Monitor: Hemispherx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) shares gained around ...
ArQule, Inc. today announced that it has entered into an exclusive license agreement with Basilea Pharmaceutica International Limited to develop and commercialize derazantinib, a pan-FGFR inhibitor in the US, EU, Japan and rest of the world excluding the People’s Republic of China, Hong Kong, Macau and Taiwan, where Sinovant Sciences Ltd., a Roivant Sciences Ltd.
Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ...
ArQule, Inc. (NASDAQ:ARQL) is attracting a substantial amount of attention in the biotechnology sector as we head into the start of a fresh week of trading, with the company serving up a degree of insight into one of its lead investigative programs and markets responding positively to the development. So what happened? Well, for anybody […] The post ArQule, Inc. Is Moving On ASCO Release, Here’s Why. appeared first on Market Exclusive.
Biotech stocks staged a recovery this week, thanks to a deal in the space and news concerning positive pipeline developments. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) gained 4.26 percent ...
NEW YORK, March 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 17th Annual Needham Healthcare Conference on March 27th, 2018, at 3:30 p.m.
ArQule, Inc. today announced that pre-clinical and clinical data on the company’s pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place in Chicago from April 14-April 18.
Measuring ArQule Inc’s (NASDAQ:ARQL) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceed expectations,Read More...
The Burlington, Massachusetts-based company said it had a loss of 9 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
NEW YORK, NY / ACCESSWIRE / March 5, 2018 / ArQule, Inc. (NASDAQ: ARQL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 5, 2018, at 9:00 AM Eastern Time. To listen ...
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, will present at the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California.
ArQule, Inc. today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m.
Stock Monitor: Regeneron Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If you ...
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Leerink Partners 7th Annual Global Healthcare Conference on February 15th, 2018, at 9:00 a.m.
Feb 7 (Reuters) - Arqule Inc: * ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA * ARQULE INC - DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL ...
Roivant Sciences and ArQule, Inc. today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR inhibitor, in Greater China.
Galectin Therapeutics Inc. (GALT) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
ArQule, Inc. today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma .